Abstract
The formation of advanced glycation end-products (AGEs), also called the Maillard reaction, occurs ubiquitously and irreversibly in patients with diabetes mellitus and its consequences are especially relevant to many inflammatory events leading to vascular dysfunctions and organ injury. The present review intends to highlight some relevant aspects of nitric oxide synthases, advanced glycation end-products and their receptors as well as the mechanisms by which AGEs are able to modulate the synthesis of nitric oxide (NO), either by NO quenching, modification of enzyme structure or regulation of gene expression. Finally, other RAGE ligands different from AGEs, but relevant to the context of inflammation, are presented as new modulators of nitric oxide synthesis.
Keywords: Advanced glycation, nitric oxide synthases, diabetic complications, hyperglycemia, inflammation, receptor for advanced glycation end-products, RAGE, ligands
Current Enzyme Inhibition
Title: Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Volume: 6 Issue: 1
Author(s): Armando Rojas, Deyarina Gonzalez, Hector Figueroa, Miguel A. Morales and Jacqueline Romero
Affiliation:
Keywords: Advanced glycation, nitric oxide synthases, diabetic complications, hyperglycemia, inflammation, receptor for advanced glycation end-products, RAGE, ligands
Abstract: The formation of advanced glycation end-products (AGEs), also called the Maillard reaction, occurs ubiquitously and irreversibly in patients with diabetes mellitus and its consequences are especially relevant to many inflammatory events leading to vascular dysfunctions and organ injury. The present review intends to highlight some relevant aspects of nitric oxide synthases, advanced glycation end-products and their receptors as well as the mechanisms by which AGEs are able to modulate the synthesis of nitric oxide (NO), either by NO quenching, modification of enzyme structure or regulation of gene expression. Finally, other RAGE ligands different from AGEs, but relevant to the context of inflammation, are presented as new modulators of nitric oxide synthesis.
Export Options
About this article
Cite this article as:
Rojas Armando, Gonzalez Deyarina, Figueroa Hector, Morales A. Miguel and Romero Jacqueline, Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes, Current Enzyme Inhibition 2010; 6 (1) . https://dx.doi.org/10.2174/157340810790712050
DOI https://dx.doi.org/10.2174/157340810790712050 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Body Mass Index, Lipid Metabolism and Estrogens: Their Impact on Coronary Heart Disease
Current Medicinal Chemistry Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Pathogenesis of Diabetic Retinopathy and Diabetic Macular Edema and Enzyme Inhibition
Current Enzyme Inhibition Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design Vascular Risk Factors and Lesions of Vascular Nature in Magnetic Resonance as Predictors of Progression to Dementia in Patients with Mild Cognitive Impairment
Current Alzheimer Research Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Pathophysiology of Erectile Dysfunction
Current Drug Targets Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Vitamin D Deficiency, Prevalence and Treatment in Neonatal Period
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycation and Antioxidants: Hand in the Glove of Antiglycation and Natural Antioxidants
Current Protein & Peptide Science Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetic Variation and Metformin Response
Current Drug Metabolism